(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 June 2011 (03.06.2011)

PCT

(10) International Publication Number
WO 2011/064399 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/24* (2006.01)

(21) International Application Number:
PCT/EP2010/068569

(22) International Filing Date:
30 November 2010 (30.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0920933.9	30 November 2009 (30.11.2009)	GB
0920940.4	30 November 2009 (30.11.2009)	GB
0920942.0	30 November 2009 (30.11.2009)	GB

(71) Applicant *(for all designated States except US)*: **BIOTEST AG** [DE/DE]; Landsteinerstrasse 5, 63303 Dreieich (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **OSTERROTH, Frank** [DE/DE]; Konrad-Adenauer-Allee 22, 63128 Dietzenbach (DE). **UHEREK, Christoph** [DE/DE]; Lachenwoerthsweg 6, 63500 Seligenstadt (DE). **BRUECHER, Christoph** [DE/DE]; Unter den Tannen 3a, 65760 Eschborn (DE). **RÖTTGEN, Peter** [DE/DE]; Stahlbühlring 129, 68526 Ladenburg (DE). **DAELKEN, Benjamin** [DE/DE]; Eleonore-Sterling-Strasse 40, 60433 Frankfurt am Main (DE). **ENGLING, André** [DE/DE]; Schweinfurter Weg 84, 60599 Frankfurt am Main (DE). **ZUBER, Chantal** [DE/DE]; Schwarzwaldstrasse 15, 60528 Frankfurt am Main (DE). **CZELOTH, Niklas** [DE/DE]; Pappelweg 9, 63303 Dreieich (DE).

(74) Agents: **DANIELS, Jeffrey Nicholas** et al.; PAGE WHITE & FARRER, Bedford House, John Street, London Greater London WC1N 2BF (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2011/064399 A1

(54) Title: HUMANIZED ANTI-IL-10 ANTIBODIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

(57) Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor α (IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL- 10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.